This narrative review evaluates the potential of immune checkpoint blockade (ICB) strategies in TP53-mutated colorectal cancer (CRC) and investigates the interplay among TP53, tumor mutational burden (TMB), and the tumor microenvironment (TME). This evidence concerns the gene TP53 and colorectal carcinoma.